Novadiscovery announces Nature Communications paper on modeling the disruption to respiratory scientific trials resulting from mitigation measures in opposition to COVID-19
Model makes use of digital populations and in silico trials to point out impression on scientific trials and recommend diversifications to trial design
Lyon, France – 13 April 2022: Novadiscovery (NOVA), a number one well being tech firm utilizing in silico scientific trials to foretell drug efficacy and optimize scientific trial improvement, at present announces the publication of a novel mannequin of respiratory tract infections (RTI) in Nature Communications to deal with the uncertainties ensuing from non-pharmaceutical interventions (NPIs) in opposition to COVID-19 on scientific trials. The paper was printed in collaboration with NOVA’s associate OM Pharma.
François-Henri Boissel, CEO, NOVA mentioned: “The pandemic and all related measures such as lockdowns seriously affected clinical trials in all indications but the impact of reduced viral transmission and resulting seasonal disease pattern disruption on respiratory trials was particularly marked. Our model provides vital information on whether trials will still meet their endpoints, how to interpret clinical relevance, and potential adaptations to statistical analyses and trial design – such as recruitment numbers – to maximise success and avoid delays in getting new treatments to patients.”
NOVA’s modeling method is rooted in methods biology and quantitative methods pharmacology. The paper describes how the mannequin was used to run in silico scientific trial simulations with OM Pharma’s OM-85 as prophylaxis for respiratory tract an infection (RTI) in digital populations and underneath numerous eventualities of lowered viral transmissions resulting from NPIs.
The outcomes have led the paper’s authors to advocate for reporting various metrics of profit, the usage of adaptive trial design and tailored statistical analyses. The authors additionally warned that eligibility standards for sufferers into trials will must be reassessed as illness burden has been impacted by pandemic measures.
The full paper, ‘Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions’, may be discovered right here.
For extra info, please contact:
François-Henri Boissel, Chief Executive Officer
Consilium Strategic Communications
Sukaina Virji, Kris Lam, Isabelle Abdou
Novadiscovery is a number one well being tech firm utilizing in silico scientific trials to foretell drug efficacy and optimize scientific trial improvement. The Company goals to enhance R&D productiveness and maximize affected person outcomes by predicting the scientific good thing about a possible new drug candidate via laptop simulation, forward of human trials.
Novadiscovery’s progressive method leverages illness modeling and simulation experience accrued over the previous decade and combines mathematical fashions of illnesses and potential new therapies with digital sufferers in its built-in scientific trial simulation platform, JINKO®.
Novadiscovery is headquartered in Lyon, France and has a workforce of round 30 scientists, engineers & clinicians who work on the interface of biology, pharmacology, arithmetic & laptop science.
For extra info, please go to https://www.novadiscovery.com and observe us on Twitter @novadiscovery and linkedin.com/firm/novadiscovery
Leave a Reply